Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab and Depigoid in Seasonal Allergic Asthma and Rhinoconjunctivitis
NCT00396409Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2006
- Primary completion
- Aug 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of omalizumab in allergic asthma, Seasonal Allergic Rhinoconjunctivitis (SAR), sponsored by Novartis. Started Feb 2006; status: completed.
02
Drugs
omalizumab
03
Conditions
allergic asthmaSeasonal Allergic Rhinoconjunctivitis (SAR)
Beyond the preview
Go deeper on NCT00396409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00396409.